Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sperfeld, A. D.
Right arrow Articles by Hanemann, C. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sperfeld, A. D.
Right arrow Articles by Hanemann, C. O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 5, 996-1004, May 2002
© 2002 Guarantors of Brain

Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2

A. D. Sperfeld1, C. Hein2, J. M. Schröder3, A. C. Ludolph1 and C. O. Hanemann1

1 Department of Neurology and 2 Department of Neurosurgery, University of Ulm and 3 Institut für Neuropathologie, Universitätsklinikum, Rheinisch-Westfälische Technische Hochschule Aachen, Germany

Correspondence to: C. O. Hanemann, Department of Neurology, Zentrum für Klinische Forschung, University of Ulm, Helmholtzstrasse 8/1, 89081 Ulm, Germany E-mail: oliver.hanemann{at}medizin.uni-ulm.de

Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder characterized by the occurrence of bilateral vestibular schwannomas, various brain and spinal tumours as well as peripheral nerve tumours, cutaneous tumours and juvenile posterior lenticular opacity. NF2 is caused by mutations in both alleles of a tumour suppressor gene coding for a protein called schwannomin or merlin. It is suggested that the development of NF2 tumours is caused by complete inactivation of the merlin/schwannomin gene. Interest ingly, in a NF2 mouse model, peripheral nerve pathology was more frequently described than schwannomas. However, review of the literature shows that patients suffering from NF2 seldom have unexplained clinical features of peripheral nerve lesion unrelated to tumour masses. Single case reports describe sural nerve biopsies, which histologically show onion-bulb-like formations, seemingly originating from Schwann cells. We have conducted a systematic investigation to determine the occurrence and aetiology of peripheral nerve involvement in NF2 patients. We investigated 15 patients with definite NF2 and in 10 of these found electrophysiological evidence of neuropathy. In this study we present the classification of neuropathy, correlation to clinical findings, and histological findings of a sural nerve biopsy. We conclude that peripheral neuropathy, mostly of axonal type, is a common clinical finding in NF2. We hypothesize that the aetiology of this frequent peripheral neuropathy syndrome in NF2 is caused by compression effects of multiple tumourlets, originating along the length of the peripheral nerves on adjacent nerve fibres, by local influences of the endoneurial pathological cells on adjacent nerve fibres and/or the inability of these cells to properly adhere to, or ensheath, the axon.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
N. Denisenko, C. Cifuentes-Diaz, T. Irinopoulou, M. Carnaud, E. Benoit, M. Niwa-Kawakita, F. Chareyre, M. Giovannini, J.-A. Girault, and L. Goutebroze
Tumor Suppressor Schwannomin/Merlin Is Critical for the Organization of Schwann Cell Contacts in Peripheral Nerves
J. Neurosci., October 15, 2008; 28(42): 10472 - 10481.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. O. Hanemann
Magic but treatable? Tumours due to loss of Merlin
Brain, March 1, 2008; 131(3): 606 - 615.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
R E Ferner, R A C Hughes, S M Hall, M Upadhyaya, and M R Johnson
Neurofibromatous neuropathy in neurofibromatosis 1 (NF1)
J. Med. Genet., November 1, 2004; 41(11): 837 - 841.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
A. Drouet, P. Wolkenstein, J.-P. Lefaucheur, S. Pinson, P. Combemale, R. K. Gherardi, P. Brugieres, J. Salama, P. Ehre, P. Decq, et al.
Neurofibromatosis 1-associated neuropathies: a reappraisal
Brain, September 1, 2004; 127(9): 1993 - 2009.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. E. Baser, J. M. Friedman, A. J. Wallace, R. T. Ramsden, H. Joe, and D. G.R. Evans
Evaluation of clinical diagnostic criteria for neurofibromatosis 2
Neurology, December 10, 2002; 59(11): 1759 - 1765.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.